RxSight Q1 Sales Fall 18.5% to $30.9M While Installed Base Tops 1,154
RXST•RxSight reported $30.9 million in Q1 sales, down 18.5%, driven by 27,472 Light Adjustable Lens units and 20 Light Delivery Devices expanding the installed base to 1,154. Gross margin rose to 76.1%, expenses rose to $41.3 million, net loss widened to $15.9 million, and New Zealand approval broadens global footprint.
1. First Quarter Financial Results
In Q1 2026, RxSight reported sales of $30.9 million, down 18.5% year-over-year, with LAL procedures falling 0.4%. Gross margin improved to 76.1%, operating expenses rose to $41.3 million, net loss expanded to $15.9 million ($0.38/share), and cash and investments stood at $217.9 million.
2. Strategic Highlights and Clinical Data
Commercial momentum included 27,472 Light Adjustable Lens units and sales of 20 Light Delivery Devices, increasing the installed base to 1,154. Regulatory approval in New Zealand extends its international footprint, and clinical presentations showed 91.2% of cases within 0.50 diopters and 93.1% achieving 20/20 or better vision.
3. 2026 Financial Guidance
RxSight maintained its full-year revenue outlook of $120–135 million and gross margin target of 70–72%, while expecting operating expenses at the high end of $150–160 million and non-cash stock-based compensation of $30–32 million.
